Short Films in Focus: “Endless Sea” With Sam Shainberg

Key Takeaways

• Film spotlights US healthcare cost barriers
• Brenda Cullerton delivers breakthrough performance
• Director draws from real pharmacy incident
• Feature expansion “HEART” in development
• Authentic cast includes friends and non‑actors

Pulse Analysis

Sam Shainberg’s short film “Endless Sea” uses a single Valentine’s Day shift to dramatize the precariousness of low‑wage workers facing soaring prescription costs. The protagonist, Carol, a flower‑delivery employee, scrambles for cash to afford a tier‑4 heart medication co‑pay of $365, highlighting how insurance tiering can push essential drugs out of reach. By framing the struggle as a tense thriller, the film turns an abstract policy debate into a visceral human story, underscoring the growing gap between healthcare pricing and everyday affordability in the United States.

The production leans heavily on authenticity, casting non‑actors, friends, and a first‑time actress, Brenda Cullerton, whose raw performance anchors the narrative. Shainberg drew the premise from a real encounter in a Brooklyn pharmacy, where an elderly woman’s desperation sparked the film’s seed. Casting director Eleonore Hendricks helped blend professional talent with everyday people, while on‑location shoots captured genuine street ambience. This hybrid approach mirrors neo‑realist techniques, allowing the audience to feel the immediacy of Carol’s world and reinforcing the film’s indictment of bureaucratic indifference.

Audience response has been overwhelmingly emotional, with viewers sharing personal stories of medication denial and Medicaid hurdles, confirming the film’s resonance across the country. The short serves as a proof of concept for Shainberg’s planned feature “HEART,” which will expand Carol’s story into a near‑future dystopia of New York’s working class. By spotlighting systemic price gouging, the project adds to a growing body of socially conscious cinema that pressures policymakers and investors to reconsider drug pricing structures. Support from financiers and distributors could accelerate the transition from short to feature, amplifying its impact.